Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123250 · ClinicalTrials.gov registry record · NA
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
A NA study, sponsored by PROCEPT BioRobotics.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT03123250 is a NA study that has completed, run by PROCEPT BioRobotics. The registered enrollment target is 101 participants.
The verdict
NCT03123250, a NA study, has completed, sponsored by PROCEPT BioRobotics.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
Single-arm, interventional pivotal clinical trial collecting patient data from use of the AQUABEAM System, a personalized image-guided waterjet resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue in males suffering from Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) with prostate volumes between 80 mL and 150 mL. The primary endpoints for safety and effectiveness will be measured at 3 months post-treatment. Treated subjects will be followed out to 60 months to collect long-term clinical data.
Interventions
- DEVICE Aquablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2022-12-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03123250
The ClinicalTrials.gov registry entry for NCT03123250 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PROCEPT BioRobotics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aquablation is the first listed.
NCT03123250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03123250 about?
NCT03123250 is a clinical study titled "Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II". Single-arm, interventional pivotal clinical trial collecting patient data from use of the AQUABEAM System, a personalized image-guided waterjet resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue in males suffering from Lower Urinary Tract Symptoms (LUTS...
What is the current status of trial NCT03123250?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2017-08-14. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT03123250?
The interventions under investigation include: Aquablation (DEVICE).
Who is sponsoring clinical trial NCT03123250?
This trial is sponsored by PROCEPT BioRobotics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.